On November 1, 2024, Novo Nordisk reported that their drug semaglutide 2.4 mg significantly improved liver fibrosis and resolved steatohepatitis in the ESSENCE trial with 37% of treated participants showing improvement versus 22.5% for placebo at 72 weeks.